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Soluble epoxide hydrolasea b s t r a c t
The roles of CYP lipid-metabolizing pathways in endothelial cells are poorly understood. Human endo-
thelial cells expressed CYP2J2 and soluble epoxide hydrolase (sEH) mRNA and protein. The TLR-4 agonist
LPS (1 lg/ml; 24 h) induced CYP2J2 but not sEH mRNA and protein. LC–MS/MS analysis of the stable
commonly used human endothelial cell line EA.Hy926 showed active epoxygenase and epoxide hydro-
lase activity: with arachidonic acid (stable epoxide products 5,6-DHET, and 14,15-DHET), linoleic acid
(9,10-EPOME and 12,13-EPOME and their stable epoxide hydrolase products 9,10-DHOME and 12,13-
DHOME), docosahexaenoic acid (stable epoxide hydrolase product 19,20-DiHDPA) and eicosapentaenoic
acid (stable epoxide hydrolase product 17,18-DHET) being formed. Inhibition of epoxygenases using
either SKF525A or MS-PPOH induced TNFa release, but did not affect LPS, IL-1b, or phorbol-12-myris-
tate-13-acetate (PMA)-induced TNFa release. In contrast, inhibition of soluble epoxide hydrolase by
AUDA or TPPU inhibited basal, LPS, IL-1b and PMA induced TNFa release, and LPS-induced NFjB p65
nuclear translocation. In conclusion, human endothelial cells contain a TLR-4 regulated epoxygenase
CYP2J2 and metabolize linoleic acid > eicosapentaenoic acid > arachidonic acid > docosahexaenoic acid
to products with anti-inflammatory activity.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Arachidonic acid is metabolised to families of biologically active
mediators by cyclooxygenase, lipoxygenase and cytochrome P450
(CYP) pathways [1,2]. Unlike COX and lipoxygenase products, the
roles of CYP pathways in vascular biology remains poorly under-
stood. CYPs metabolise arachidonic acid in several ways: (i) epoxy-
genases metabolise arachidonic acid to epoxyeicosatrienoic acids
(EETs); (ii) lipoxygenase-like CYPs generate mid-chain hydroxyei-
cosatetraenoic acids (HETEs); and (iii) the x- and x-1-hydroxylase
CYPs produce x-terminal HETEs [2]. In addition to arachidonic
acid, these lipid metabolising CYPs can also metabolise linoleic acid
(LA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA),to structurally related epoxy-products [3]. CYP2 family members
are the main fatty acid-metabolising CYPs. Of this larger family,
the CYP2J and CYP2C subfamilies represent the most important
fatty acid epoxygenases [2–6].
In most organs, epoxygenase products are short-lived due to
rapid metabolism. The major pathway of EET metabolism is via
epoxide hydrolases [7], which convert EETs to dihydroxy deriva-
tives called DHETs [8]. Although other enzymes possess epoxide
hydrolase activity, soluble epoxide hydrolase (sEH) appears to be
the key enzyme in this pathway, as genetic disruption or pharma-
cological inhibition of sEH elevates EETs, and reduces neointima
formation [9], atherosclerosis, abdominal aortic aneurysm, and
dyslipidaemia in hyperlipidaemic mice [10]. Knockout or inhibi-
tion of she also causes hypertension [11] and diabetes [12] in
mouse models. The elevation of EETs by sEH inhibitors is now con-
sidered a potentially important therapeutic goal for management
of cardiovascular and inflammatory disorders [13].
Primary endothelial cells use complex growth media and
change phenotype with passage. EA.Hy926 are commonly used
stable human cell line derived from human umbilical vein
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retain many endothelial cell characteristics [14]. Here we have
characterized the lipid metabolizing CYP, lipoxygenase and cyclo-
oxygenase pathways in EA.Hy926 cells, and investigated whether
they represent a simple model to test the anti-inflammatory
actions of sEH inhibitors. Our results show human endothelial cells
contain TLR-4 inducible CYP2J2. As a model for this induction,
EA.Hy926 actively metabolizes AA, LA, DHA, and EPA to epoxygen-
ase metabolites, and sEH inhibitors strongly inhibit inflammation-




carbonyl]amino]-dodecanoic acid) and TPPU (N-[1-(1-oxopropyl)-
4-piperidinyl]-N0-[4-(trifluoromethoxy)phenyl)-urea) were from
Cayman Chemical Company (Cambridge Bioscience, Cambridge,
UK). SKF525A (a-phenyl-a-propyl-2-(diethylamino)ethyl ester-
benzeneacetic acid) was from Biomol (Affiniti Research Products,
Exeter, UK). Human TNFa ELISA was from eBioscience (Hatfield,
UK). Rabbit anti-p65 was from Santa Cruz (Heidelberg, Germany),
while rabbit anti-CYP2J2 and anti-sEH were from Biorybt
(Cambridge, UK). Taqman primers and reagents were from
Invitrogen (Paisley, Renfrewshire, UK). Recombinant human
IL-1b was from R&D Systems (Abingdon, Oxfordshire, UK). Unless
stated, all other reagents were from Sigma–Aldrich (Poole, Dorset,
UK).2.2. Cell and tissue culture
EA.Hy926 (ATCC; LGC Standards, Middlesex, UK) were cultured
in M199 supplemented with antibiotic/antimycotic mix, and 10%
FBS; 37 C; 5% CO2; 95% air. HAEC used at passage 3–4, were from
PromoCell and grown according the manufacturer’s recommended
conditions. Human blood out-growth endothelial cells were a gift
from Prof. Jane Mitchell (Imperial College London). Since FBS inter-
feres with lipid substrate composition, and the release and detec-
tion of eicosanoids (M. Edin, unpublished observations), all
experiments were performed with M199 supplemented with anti-
biotic/antimycotic mix, without FBS. Detection of eicosanoids by
liquid chromatography tandem mass spectrometry was performed
as previously described [27].2.3. RT-PCR and real-time qRT-PCR
Total RNA was extracted using Qiagen’s QiaAmp RNA Blood
Mini Kit as per the manufacturer’s instructions. qRT-PCR for
CYP2J2, and sEH (ephx2) was measured by the Taqman qRT-PCR
ddCt method and normalized to GAPDH levels, using a Corbett Ro-
tor-Gene 6000 machine.2.4. Immunoassays, and EET measurements
TNFa ELISAs were performed according to manufacturer’s
instructions. In these experiments cell viability by MTT assays
were performed as previously described [15]; and there were no
significant changes between treatments groups. Immunofluores-
cence was performed essentially as previously described using
primary antibody dilutions of 1:50–1:100 [15]. LC–MS/MS analysis
of epoxygenase products in culture supernatants was as previously
described [16].3. Results
3.1. Profile of lipid metabolizing CYPs and their products in EA.Hy926
EA.Hy926, human aortic endothelial cells, and human blood
outgrowth endothelial cells contained CYP2J2 and sEH mRNA and
protein (Fig. 1). The TLR-4 ligand LPS (1 lg/ml) induced CYP2J2
mRNA (4 h) and protein (24 h) (Fig. 1). In contrast, sEH mRNA
and protein levels remained relatively stable following LPS treat-
ment (Fig. 1).
As a stable endothelial cell line we chose to study EA.Hy926
further. Over 24 h EA.Hy926 released detectable levels of the epox-
ygenase products of AA [14,15-DHET]; LA [9,10-epoxy-octadece-
noic acid (EPOME), 12,13-EPOME and their respective diol
products 9,10-DHOME, and 12,13-DHOME]; DHA [19,20-dihy-
droxy-docosapentaenoic acid (DiHDPA)]; and EPA [17,18-DHET;
the most abundant epoxygenase product detected under basal
culture conditions] (Fig. 2A). LA but not AA lipoxygenase products
9-, and 13-HODE were also detected basally (Fig. 2B), as were the
cyclo-oxygenase products PGF2a, PGD2 and PGE2 (Fig. 2C).
When stimulated with the TLR-4 ligand LPS (1 lg/ml; 24 h),
12,13-DHOME, 5,6-DHET and in particular 9,10-DHOME release
was stimulated (Fig. 2A). LPS also stimulated release of 9- and
13-HODE, and 12- and 8-HETE (Fig. 2B), but not COX products
(Fig. 2C).
3.2. Endogenous epoxygenase activity inhibits TNFa release in
EAHy926 cells
EA.Hy926 cells were treated with vehicle (0.01% DMSO) or the
chemically distinct epoxygenase inhibitors MS-PPOH or SKF525A
(10 lM each; 7 h). Vehicle treated EA.hy926 cells produced
19.8 pg/ml of TNFa. Treatment with either MS-PPOH or SKF525A
induced an approximate 3-fold increase in TNFa production
(Fig. 3A). In the presence of high concentrations of the inflamma-
tory stimuli IL-1b (10 ng/ml), PMA (5 nM) or LPS (1 lg/ml),
MS-PPOH co-incubation had no additional effect on TNFa release
(Fig. 3B).
3.3. Soluble epoxide hydrolase inhibitors are anti-inflammatory in
EAHy926 cells
Treatment with 10 lM AUDA significantly reduced TNFa secre-
tion in the absence of inflammatory stimuli, and abolished PMA
(5 nM), LPS (1 lg/ml) or IL-1b (10 ng/ml) stimulated TNFa release
(7 h; Fig. 4A). Moreover, treatment with AUDA (10 lM) or TPPU
(1 lM) inhibited LPS (1 lg/ml; 2 h)-induced nuclear localization
of the NFjB p65 subunit (Fig. 4B).4. Discussion
Here we show human endothelial cells contain a TLR-4 induc-
ible CYP2J2 epoxygenase. In addition, we show EA.hy926 are a
useful, simple, and reproducible humanmodel system to study this
inducible CYP epoxygenase enzyme pathway and sEH inhibitors.
Under basal conditions, the release of AA epoxygenase/sEH
product 14,15,DHET, the linoleic acid products 9,10-EPOME and
12,13-EPOME (and 9,10-DHOME and 12,13-DHOME), the DHA
product 19,20-DiHDPA, and the EPA product 17,18-DHET were all
detectable in EA.Hy926 conditioned media. All these products are
also produced by vascular tissue (e.g., rat aorta; DBB, ME, DCZ
unpublished observations), and in the circulation of healthy
volunteers [17]; however the actions of many of these lipid
metabolites, including those produced in the largest amounts
(e.g., 17,18-DHET) are still poorly understood. Exogenous
Fig. 1. Expression and regulation of CYP2J2 and sEH by LPS in human endothelial cells. (A) qRT-PCR (4 h) and (B) immunofluorescent analysis (24 h) of CYP2J2 and sEH
expression in EA.Hy926 treated with LPS (1 lg/ml). qRT-PCR data represent relative expression compared to GADPH as mean ± SEM from n = 4 separate experiments. (C)
qRT-PCR (4 h) of human blood out growth endothelial cells and (D) immunofluorescent analysis (24 h) of CYP2J2 in human primary aortic endothelial cells treated with LPS
(1 lg/ml). qRT-PCR data represent relative expression compared to GADPH as mean ± SEM from n = 3 separate donors. ⁄ indicates p < 0.05 by one-sample t-test between
control and LPS treatment. Immunofluorescent micrographs are representative of n = 3 experiments. As a negative control, in some experiments primary antibody was
omitted (2 Ab) which showed no specific staining.
Fig. 2. Oxylipin product profile of control and LPS stimulated EA.Hy926 endothelial cells. LC/MS/MS analysis of the (A) epoxygenase, (B) lipoxygenase and (C)
cyclo-oxygenase products release (pg/ml) from EA.Hy926 untreated or treated with LPS (1 lg/ml) for 24 h. Data represents the mean ± SEM from n = 3. ⁄ indicates p < 0.05 for
each analyte by unpaired t-test between control and LPS treatment.
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alpha subunit [19], inhibits ristocetin-induced thrombus formation
[20], and exerts negative chronotropic effects and protects neona-
tal rat cardiomyocytes against Ca2+-overload [21]. Any effects on
endothelial cells themselves have yet to be described, so warrant
further investigation.
We recently showed CYP2J2 is induced by LPS in human
peripheral blood monocytes and monocyte cell lines [22]. CYP2J2
is expressed in endothelial cells under basal conditions and is
similarly induced by the TLR-4 ligand LPS in endothelial cells.
This induction of CYP2J2 was accompanied by increases in9,10-DHOME, 12,13-DHOME and 5,6-DHET formation. These find-
ings indicate that CYP2J2 is a more general inflammation-induced
enzyme than perhaps previously thought. EA.Hy926 cells also
express CYP2C8 but not CYP2C9 mRNA (Fig. 1), which showed no
sign of induction with LPS. Although EPA and DHAmay be rate limit-
ing in this system for their ownmetabolite formation, our results indi-
cate that the LPS inducible eicosanoids are froman inducible CYP such
as CYP2J2, while the non-inducible products (e.g., 17,18-EET) may
derive more from non-TLR-4 regulated enzymes such as CYP2C8.
Epoxygenase pathway metabolites regulate endothelial
cell adhesion molecule expression [3]. Our results now show
Fig. 3. Epoxygenase inhibition induces TNFa release from EAHy926 endothelial cells. (A) Fold TNFa release (7 h) from EA.Hy926 treated with vehicle control (0.01% DMSO),
or epoxygenase inhibitor, MS-PPOH (10 lM) or SKF525A (10 lM). Data represents mean ± SEM from n = 7 replicates from 4 separate experiments. ⁄ indicates p < 0.05 by one-
sample t-test between control and epoxygenase inhibitors. (B) Fold TNFa release (7 h) from EA.Hy926 treated with vehicle control (0.01% DMSO), 5 nM PMA, 1 lg/ml LPS or
10 ng/ml IL-1b in the presence of absence of 10 lM MS-PPOH. Data represents mean ± SEM from n = 5 replicates from 4 separate experiments. ⁄ indicates p < 0.05 by one-
sample t-test between control and inflammatory stimuli inhibitors.  indicates p < 0.05 by one-sample t-test between treatment in presence or absence of MS-PPOH.
Fig. 4. sEH inhibition limits basal and inflammation induced TNFa release from EAHy926 endothelial cells. (A) TNFa release (fold from control; 7 h) from EA.Hy926 treated
with vehicle control (0.01% DMSO), 5 nM PMA, 1 lg/ml LPS or 10 ng/ml IL-1b in the presence of absence of the sEH inhibitor AUDA (10 lM). Data represents mean ± SEM from
n = 8 replicates from 4 separate experiments. ⁄ indicates p < 0.05 by paired t-test between treatment in presence or absence of AUDA. (B) EA.Hy926 were treated with LPS
(1 lg/ml; 2 h) to induce p65 nuclear localization. Scale bar 50 l. LPS induced p65 nuclear localization is absent or strongly diminished in cells treated with sEH inhibitors
TPPU (1 lM; middle panels) or AUDA (10 lM; lower panels). 2nd Ab control shows immunofluorescence levels when primary antibody was omitted. Each panel was
enhanced by 20% brightness and 20% contrast in PowerPoint to aid visualization. Data is representative of n = 3 experiments.
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matory actions of endothelial epoxygenases. TNFa is a potent
inflammatory activator of endothelial cells [23] and is critical to
the pathogenesis of many inflammatory diseases, most notably
rheumatoid arthritis [24]. sEH inhibitors with their anti-inflamma-
tory and analgesic profile [25,26] may therefore represent a viable
treatment for highly inflammatory disorders such as rheumatoid
arthritis. Although we may assume the actions of sEH inhibition
in endothelial cells is due to the direct elevation of epoxygenase
products acutely, it is also important to note that following sEH
inhibition, endothelial epoxygenase products also get incorporated
into cell membranes (potentially for future release) as well as get
metabolized via b-oxidation to form novel lipid species such as
10,11-epoxy-hexadecadienoic acid (16:2) and 8,9-epoxy-myristo-
leic acid (14:1) whose functions are not known [27], and are rarely
measured.
Primary endothelial cells are responsive to IL-1b, LPS and PMA
[28]. The fact that EA.Hy926 respond similarly further supports
their use as an in vitro cell line to model physiological effects of
EETs. Chemically distinct epoxygenase inhibitors SKF525A and
MS-PPOH increased TNFa production. This suggests, similar to
our recent report on monocytes [29], that EET production helpsto maintain inflammatory homeostasis. The stronger TNFa release
induced by the classical endothelial cell activators IL-1b, LPS or
PMA, was not further elevated by epoxygenase inhibition, suggest-
ing a common pathway e.g., NFjB, critical for TNFa release, is
being used by both pathways.
Although EA.Hy926 cells appear to be a good model to study
epoxygenase products and activity, they are not without their lim-
itations when compared to primary endothelial cells. Importantly,
in our hands the cyclooxygenase system was relatively inactive,
and no prostacyclin could be detected under any condition, includ-
ing following LPS stimulation (Fig. 2C).
Endothelial cells and EA.Hy926 cells actively metabolize
different fatty acid substrates to a variety of biologically active
fatty acyl/oxy-lipins. There has been intensive interest in the
mechanistic basis for the effect of diets rich in different sources
of fatty acids (e.g., the Mediterranean diet, diets rich in x6-polyun-
saturated fatty acids, or fish oil supplementation), and their effects
on cardiovascular biology [30]. Modifying substrates and diet may
therefore change the balance of oxylipins and may be responsible
for the purported benefits of these lifestyle modifications. Moreover,
changing the substrate itself not only alters mediator production
but also can change the balance of mediators produced by regulating
A.A. Askari et al. / Biochemical and Biophysical Research Communications 446 (2014) 633–637 637phospholipase activation. Interestingly, when we gave AA (10 mM)
acutely to EA.Hy926 cells, we did induce AA products 5,6-DHET
and HETEs, however we also strikingly induced LA product
EPOMEs and DHOMEs (Fig. 2). In contrast, 14,15-DHET, 17,18-DHET,
and 19,20-DiHDPA were all reduced. Therefore in this simple
system, just substrate delivery to the epoxygenase enzymes is far
more complex than would be originally predicted.
In summary, endothelial cells contain an anti-inflammatory
TLR-4 inducible epoxygenase. In addition, EA.Hy926 cells represent
a useful tool to study the anti-inflammatory actions of the epoxy-
genase pathway metabolites and soluble epoxide hydrolase inhib-
itors in vascular endothelial cells.
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